BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 8876671)

  • 1. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
    Agarwal R; Mohan RR; Ahmad N; Mukhtar H
    Mol Carcinog; 1996 Sep; 17(1):13-22. PubMed ID: 8876671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.
    Khan SG; Dummer R; Siddiqui J; Bickers DR; Agarwal R; Mukhtar H
    Biochem Biophys Res Commun; 1996 Mar; 220(3):795-801. PubMed ID: 8607844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion.
    Tennenbaum T; Lowry D; Darwiche N; Morgan DL; Gartsbein M; Hansen L; De Luca LM; Hennings H; Yuspa SH
    Cancer Res; 1998 Apr; 58(7):1435-43. PubMed ID: 9537245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin.
    Owens DM; Spalding JW; Tennant RW; Smart RC
    Cancer Res; 1995 Jul; 55(14):3171-8. PubMed ID: 7606738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mouse epidermis coexpressing transforming growth factor-alpha and v-fos: acceleration of autonomous papilloma formation and malignant conversion via c-Ha-ras activation.
    Wang XJ; Liefer KM; Greenhalgh DA; Roop DR
    Mol Carcinog; 1999 Dec; 26(4):305-11. PubMed ID: 10569807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.
    Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA
    Cancer Res; 2006 Feb; 66(3):1302-12. PubMed ID: 16452183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against malignant conversion of chemically induced benign skin papillomas to squamous cell carcinomas in SENCAR mice by a polyphenolic fraction isolated from green tea.
    Katiyar SK; Agarwal R; Mukhtar H
    Cancer Res; 1993 Nov; 53(22):5409-12. PubMed ID: 8221679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ras protein p21 processing enzyme farnesyltransferase in chemical carcinogen-induced murine skin tumors.
    Agarwal R; Khan SG; Athar M; Zaidi SI; Bickers DR; Mukhtar H
    Mol Carcinog; 1993; 8(4):290-8. PubMed ID: 8280377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of retinoic acid receptors in mouse skin and skin tumors is associated with activation of the ras(Ha) oncogene and high risk for premalignant progression.
    Darwiche N; Scita G; Jones C; Rutberg S; Greenwald E; Tennenbaum T; Collins SJ; De Luca LM; Yuspa SH
    Cancer Res; 1996 Nov; 56(21):4942-9. PubMed ID: 8895748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
    Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
    Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of mutated Ha-ras during premalignant progression in SENCAR mouse skin.
    Rodriguez-Puebla ML; LaCava M; Bolontrade MF; Russell J; Conti CJ
    Mol Carcinog; 1999 Nov; 26(3):150-6. PubMed ID: 10559789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent codon 12 Ki-ras mutations in mouse skin tumors initiated by N-methyl-N'-nitro-N-nitrosoguanidine and promoted by mezerein.
    Rehman I; Lowry DT; Adams C; Abdel-Fattah R; Holly A; Yuspa SH; Hennings H
    Mol Carcinog; 2000 Apr; 27(4):298-307. PubMed ID: 10747294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased c-kit function inhibits enhanced skin carcinogenesis in c-Ha-ras protooncogene transgenic mice.
    Muto S; Katsuki M; Horie S
    Cancer Sci; 2007 Oct; 98(10):1549-56. PubMed ID: 17683512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against induction of mouse skin papillomas with low and high risk of conversion to malignancy by green tea polyphenols.
    Katiyar SK; Mohan RR; Agarwal R; Mukhtar H
    Carcinogenesis; 1997 Mar; 18(3):497-502. PubMed ID: 9067548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary fat and colon cancer: modulating effect of types and amount of dietary fat on ras-p21 function during promotion and progression stages of colon cancer.
    Singh J; Hamid R; Reddy BS
    Cancer Res; 1997 Jan; 57(2):253-8. PubMed ID: 9000564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic coexpression of v-Ha-ras and transforming growth factor alpha increases epidermal hyperproliferation and tumorigenesis and predisposes to malignant conversion via endogenous c-Ha-ras activation.
    Wang XJ; Greenhalgh DA; Roop DR
    Mol Carcinog; 2000 Mar; 27(3):200-9. PubMed ID: 10708482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K; Nagasu T
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.